Journal of Blood Medicine
Volume 7, 2016 - Issue
Open access
481
Views
131
CrossRef citations to date
0
Altmetric
Review
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
Johanna Mondesir1 Service d’Immunopathologie Clinique, Hôpital Saint Louis;2 CNRS UMR8104, INSERM U1016, Institut Cochin, Université Paris Descartes, Paris
, Christophe Willekens3 Gustave Roussy, Université Paris-Saclay, Service d’Hématologie Clinique;4 INSERM U1170, Gustave Roussy, Université Paris-Saclay, Villejuif;5 Faculté de médecine Paris-Sud, Kremlin-Bicêtre
, Mehdi Touat6 AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière – Charles Foix, Service de Neurologie 2-Mazarin, Paris;7 Gustave Roussy, Université Paris-Saclay, Département d’Innovation Thérapeutique et d’Essais Précoces, Villejuif, France
& Stéphane de Botton3 Gustave Roussy, Université Paris-Saclay, Service d’Hématologie Clinique;4 INSERM U1170, Gustave Roussy, Université Paris-Saclay, Villejuif;5 Faculté de médecine Paris-Sud, Kremlin-BicêtreCorrespondence[email protected]
Pages 171-180
|
Published online: 02 Sep 2016
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.